Analyst ratings and price targets can significantly influence investor sentiment and stock performance. In this case, RBC Capital's reiteration of a 'Sector Perform' rating suggests that they expect PTC Therapeutics' stock to perform in line with the sector average. The maintained $49 price target indicates their belief that the stock is fairly valued at this price. This could potentially maintain the stock's current price level, hence the neutral score.